GSGuoliang Shao

Guoliang Shao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guoliang Shao has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Chunyi Hao

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Hepato-Pancreato-Biliary Surgery, Sarcoma Center, Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication
  • Fengyong Liu

    Department of Interventional Radiology, Senior Department of Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

    1 shared publication
  • Jia-Mei Yang

    Department of Special Treatment, Eastern Hepatobiliary Surgery Hospital, Shanghai, China

    1 shared publication
  • Jie Zhou

    Department of Hepatobiliary Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, China

    1 shared publication
  • Jijin Yang

    Department of Interventional Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China

    1 shared publication
  • Kefeng Dou

    Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, China

    1 shared publication

Latest Publications

  • Open Access

    Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

    by Sheng-Long Ye, Jiamei Yang, Ping Bie, Shuijun Zhang, Xiaoping Chen, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, et al.

    This study aimed to investigate the safety of sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients. A subgroup of 345 Chinese patients from the international database of the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study was included in this analysis. Safety assessment measures were adverse events (AEs) and serious adverse events (SAEs) graded using the National Cancer Institute Common Terminology Criteria version 3.0. Of 331 evaluable patients, 98% started sorafenib at 800 mg/day. The median treatment duration was 22 weeks (range, 0.1–116 weeks), and median overall survival (OS) was 322 days (10.7 months). Approximately 50% of patients had at least one adverse event, and 6% had grade 3–4 adverse events. Drug-related adverse events were experienced by 29% of patients, and 3.6% had grade 3–4 drug-related adverse events. Overall, 23% of patients (n = 77) experienced serious adverse events, among which only 1 event was drug-related (0.3%). No differences in overall adverse events, serious adverse events, and deaths were observed between Child-Pugh A and Child-Pugh B patients. The most frequent drug-related adverse events were dermatological/skin (24%), hand-foot skin reaction (20%), gastrointestinal (11%), and diarrhea (11%). The majority of adverse events occurred within 30 days of beginning sorafenib. Sorafenib has satisfactory efficacy and safety in Chinese Child-Pugh A and B patients with unresectable HCC using the recommended dosage of 800 mg/day, and the safety of sorafenib is not affected by liver function. Prophylaxis for gastrointestinal adverse events may help to decrease dose interruptions or discontinuation. ClinicalTrials.gov ; Identifier: NCT00812175. Date of registration: December 19, 2008.